Valued at USD 1.41 billion in 2021, the carrier screening market is projected to reach USD 3.64 billion by 2030, growing at a CAGR of 11.7% during the forecast period of 2022–2030. Key players include MedGenome, Myriad Genetics, Natera Inc., Opko Health, Quest Diagnostics Incorporated, Roche AG, Sequenom Inc., Thermo Fisher Scientific Inc., and True Health. This article reviews technology and end-user segmentation, regional leadership and recent product launches in the carrier screening market.

Segmentation Across Type, Technology and End-User

Polaris segments the carrier screening market by type, medical condition, technology, end-user and region. Within type, targeted disease carrier screening sits alongside expanded screening formats. Technology is split into DNA sequencing, polymerase chain reaction, microarrays and other technologies, while end-users include hospitals, reference laboratories, physician offices and clinics, and other end users. By medical condition, the market covers pulmonary, hematological, neurological and other conditions, and expanded testing is offered through customized and predesigned panels.

The DNA sequencing segment was the most significant revenue contributor in 2021 and is expected to retain its dominance, owing to developments in genetic analytical techniques such as assays based on next-generation sequencing and microarray technology, together with molecular diagnostics. Reference laboratories and hospitals are therefore natural channels for suppliers of sequencing-based tests.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/carrier-screening-market

Regional Outlook for the Carrier Screening Market

North America held the highest market share in 2021, supported by a rise in pulmonary, hematological and neurological disorders that fuels the need for testing. Asia Pacific is anticipated to witness the highest market growth rate globally, as a rising population with genetic illnesses and the increasing popularity of test kits drive growth. Advances in genomic medicine have also enabled low-cost, pan-ethnic, broadened screening that lets obstetric healthcare professionals screen for more than 100 recessive genetic illnesses.

Prenatal and Reproductive Healthcare Applications

Molecular screening tests help provide adequate prenatal and reproductive healthcare, which aids the management of heritable disorders. Many genetic diseases are detectable early in pregnancy, and customer demand for safe and effective carrier tests propels the market. Predictive and presymptomatic testing identifies risk before symptoms emerge, and carrier testing advises a couple about their chances of having a child with a genetic problem. Healthcare organizations in several countries are also financing newborn testing to predict disorders that may emerge later in life.

Recent Developments Reshaping Competition

In August 2025, Natera launched Fetal Focus, a non-invasive prenatal testing solution designed to identify fetal mutations associated with multiple autosomal recessive single-gene conditions, such as cystic fibrosis, spinal muscular atrophy, alpha-thalassemia and beta-hemoglobinopathies. The test uses a maternal blood sample and works effectively even without a biological father's sample.

Earlier, in September 2025, PacBio revealed its entry into high-throughput carrier screening by expanding its PureTarget product line, which lets laboratories combine several specialized assays into one scalable test powered by HiFi sequencing.

In May 2025, CENTOGENE introduced its Reproductive Genetics Portfolio, which includes preimplantation genetic testing for aneuploidy (PGT-A) and an expanded carrier screening service. The PGT-A offering leverages a database of more than one million sequences and provides an optional rapid turnaround of up to 24 hours for IVF embryos. Its CentoScreen carrier screening service covers 332 genes with at least 99% coverage and is available for individuals or couples, supporting early identification of inherited genetic risks.

Strategic Takeaways

The evidence points to convergence between carrier testing, non-invasive prenatal testing and preimplantation genetic testing in reproductive care. Suppliers that pair DNA sequencing capability with broad gene coverage and laboratory partnerships are positioned for the shift, although high test prices and limited awareness remain constraints noted by Polaris. Carrier screening can cost between $100 and $2,000 depending on the sensitivity of the test, and many people worldwide remain unaware of its benefits.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market